<DOC>
	<DOCNO>NCT01166217</DOCNO>
	<brief_summary>PF-04620110 novel compound propose treatment Type 2 diabetes mellitus . The primary purpose trial evaluate relative bioavailability three different oral dose formulation PF-04620110 .</brief_summary>
	<brief_title>A Single Dose Study Of PF-04620110 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 21 55 year Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding screen .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Single Dose Study Healthy Subjects</keyword>
</DOC>